Business
Viemed Healthcare Announces First Quarter 2025 Financial Results
LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, r
About this update from Viemed Healthcare, Inc.
[{"type":"image","alt":"Viemed Healthcare, Inc.","displaySize":"","headline":null,"caption":"Viemed Healthcare, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/cc5a792726a74b70b3da7b0ed0a2cba1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mHuz1fZsfOPljMggXtiyQg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc5a792726a74b70b3da7b0ed0a2cba1","width":300,"height":125}},"lazy":false},{"type":"text","content":"LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025.","length":375,"tagName":"p"},{"type":"text","content":"Operational highlights (all dollar amounts are USD):","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. ","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Net income attributable to Viemed for the quarter ended March 31, 2025 totaled $2.6 million, or $0.06 per diluted share, an increase of 64% over net income attributable to Viemed of $1.6 million, or $0.04 per diluted share, for the quarter ended March 31, 2024.","length":261,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA for the quarter ended March 31, 2025 totaled $12.8 million, a 26% increase as compared to the quarter ended March 31, 2024. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.","length":319,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company increased its ventilator patient count to 11,809 as of March 31, 2025, an increase of 13% over March 31, 2024, and a slight increase as compared to December 31, 2024.","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company increased its PAP therapy patien...